Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Nueva composición farmacéutica para el carcinoma anaplásico de tiroides

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOKR20170321001
Publicado:
15/06/2017
Caducidad:
15/06/2018
Resumen:
Una empresa coreana especializada en ciencias biomédicas ha desarrollado un nuevo tratamiento para el carcinoma anaplásico de tiroides que permite curar cáncer de tiroides indiferenciado. Se trata de un compuesto sintetizado que controla el receptor de estrógeno ¿ (ERR ¿) e incrementa el índice de absorción de isótopos radiactivos en las células cancerígenas. El medicamento permite controlar el cáncer y reducir el tamaño del cáncer anaplásico de tiroides. La empresa busca socios con el fin de establecer acuerdos de licencia o continuar con la investigación y desarrollo.

Details

Tittle:
Novel pharmaceutical composition for anaplastic thyroid carcinoma
Summary:
A Korean company specialised in biomedical science has developed a new treatment for anaplastic thyroid carcinoma. The new pharmaceutical composition will enable to cure undifferentiated thyroid cancer. The company is looking for partners to make license agreement with or progress joint research and development.
Description:
A Korean SME has been interested in developing new medicines through integrating oriental and western medicine. They have 5 R-Y-D institutions and 19 pipelines including natural substances and synthetic medicines. They also have interest in intractable and rare diseases. There has been no medicine for anaplastic thyroid carcinoma which is hard to trace and treat because the tumor has a problem absorbing iodine, unlike other differentiated thyroid cancer cells. The company has developed an effective medicine for undifferentiated thyroid cancer.

Anaplastic thyroid cancer (ATC) is one of the most aggressive and lethal cancers known to affect humans. The prevalence rate of anaplastic thyroid carcinoma is relatively low compared to other types of thyroid cancer. However, once it has occurred, it has been really difficult to treat the disease. The medicine for the cancer has not been developed, so the prognosis is not good and it is connected to high death rate. Also, it has been almost impossible to cure small size of metastasized cancer, because it is invisible and untraceable.

The developed medicine from the company has solved those problems. It is a synthesized single compound that controls estrogen related receptor ¿ (ERR ¿) and increases the absorption rate of radioactive isotopes into the target cancer cells. The medicine makes it possible to track the iodinated cancer and reduce the mass size of the anaplastic thyroid cancer.

The company is interested in companies to cooperate on further research and tests together. They have finished developing the medicine and additional tests are going on. They are looking for partners to progress joint research and have license agreement.
Advantages and Innovations:
-It is almost nontoxic as a result of toxicity test.
-It is predicted to be highly secure to be used as anticancer medicine and adjuvant.
-It can increase the absorptivity of radioactive isotopes.(Iodine Uptake)
-It can be also helpful to treat the cancer which is metastasised by anaplastic thyroid carcinoma.
Stage of Development:
Available for demonstration
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
The patent is applied in Korea and international organization.(PCT)

Partner sought

Type and Role of Partner Sought:
Type of partner sought
-SME and larger company

Specific area of activity of partner
-western medicine, oriental medicine, undifferentiated thyroid cancer

Tasks to be performed by the partner sought
-Research cooperation and License agreement

Client

Type and Size of Client:
Industry SME 50-249
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English

Keywords

Technology Keywords:
06001003 Citología, cancerología, oncología
06001007 Medicina de urgencias
06001006 Vacunas humanas